PT-141 (Bremelanotide) Results Timeline
What the standard PT-141 (Bremelanotide) research protocol looks like phase by phase, over a typical 8–16 weeks (titration); as-needed thereafter cycle. This is the escalation schedule from our full dosing protocol, presented as a timeline rather than a table.
Quick Facts
FREQUENCYAs needed (not daily)
CYCLE LENGTH8–16 weeks (titration); as-needed thereafter
DOSE RANGE500–1,500 mcg per dose
ROUTESubcutaneous injection
Phase-by-Phase Timeline
Loading / Titration
Initial doses
Target dose: 500 mcg
Escalation
Standard dose
Target dose: 1,000 mcg
Maintenance
Full dose
Target dose: 1,500 mcg
This timeline reflects the structure of the standard PT-141 (Bremelanotide) research protocol documented on this site — it is not a guarantee of individual outcomes, and timelines vary between research subjects. All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.